Tech Company Financing Transactions
Evolve BioSystems Funding Round
On 5/31/2017, Evolve BioSystems secured $20 million in Series B funding from MLS Capital Fund II, Acre Venture Partners and Bow Capital.
Transaction Overview
Company Name
Announced On
5/31/2017
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
MLS Capital Fund II (Lead Investor) (Roger Wyse)
Bow Capital (Vivek Ranadive)
Horizons Ventures (Anne Lo)
Proceeds Purpose
The funds will support ongoing clinical activities, operational expansion, and the launch of the company's unique, activated probiotic and prebiotic products, which restore the infant gut microbiome to its natural state, allowing proper metabolic and immune development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2121 2nd St. B108
Davis, CA 95618
USA
Davis, CA 95618
USA
Phone
Undisclosed
Website
Email Address
Overview
Evolve Biosystems will develop and bring to market the next generation of probiotic-based biotherapeutics to establish, restore, and maintain a healthy human microbiome across a range of unmet clinical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Brown
Chief Financial Officer
Sandy Argabrite
Chief Scientific Officer
David Kyle
VP - Marketing
Christie Fleming
VP - Marketing
Brian Ostrer
VP - Operations
Robin Flannery
VP - Operations
Michael Russell
VP - R & D
Minhthy Nguyen
VP - Regulatory Affairs
Samara Freeman
Browse more venture capital transactions:
Prev: 5/31/2017: Movius venture capital transaction
Next: 5/31/2017: Data Inventions venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs